Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Frontline chemotherapy for CD30+ non-ALCL peripheral T-cell lymphoma a multi-center retrospective analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

SHSunwoo HanWJWilliam T. JohnsonEPEkta Panjrolia

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows no superior regimen for CD30+ non-ALCL T-cell lymphoma, impacting progression-free survival.

Key Points

  • To compare outcomes of different frontline chemotherapy regimens in patients with CD30+ non-ALCL peripheral T-cell lymphoma.
  • Conducted a multi-center retrospective analysis across 7 United States centers.
  • Included chemotherapy-naïve patients diagnosed with CD30+ peripheral T-cell lymphoma (≥1%).
  • Evaluated treatment outcomes based on regimens including brentuximab vedotin and etoposide.
  • Oral response rate was 72%, with 64% achieving complete response.
  • Median progression-free survival was 11.4 months, and median overall survival was 47 months.
  • No significant survival differences observed between treatment regimens.

Cite This Study

Han et al. (2025) studied this question.

synapsesocial.com/papers/69362f714fa91c937236e1adhttps://doi.org/10.1182/blood-2025-3641
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Frontline brentuximab vedotin and CHP (A+CHP) in patients (pts) with peripheral T-cell lymphoma with less than 10% CD30 expression: Results from the phase 2 SGN35-032 study.2024 · 7 citations
  2. 2Impact of DUSP22 and TP63 rearrangements in patients with ALK-negative ALCL treated with frontline BV-CH(E)P2025
  3. 3Single center retrospective evaluation of CHOP-based regimens in older patients with treatment naive blastic plasmacytoid dendritic cell neoplasm2025 · 1 citations
  4. 4Continued risk of relapse in peripheral T-cell lymphoma even in patients who achieved complete response after initial therapy2025
  5. 5Outcomes of second-line systemic therapy for relapsed or refractory peripheral T-cell lymphomas: A single-center, retrospective analysis2025